An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and I in a 4 week on, 2 week off schedule in patients with advanced solid tumors.

被引：0
|
作者：
Eskens, F. A.
Planting, A.
Van Doorn, L.
Isoe, T.
Hayashi, K.
Hussain, S.
Ekman, L.
Burger, H.
Verweij, J.
机构：
[1] Erasmus MC, Rotterdam, Netherlands
[2] Kirin Co Ltd, Tokyo, Japan
[3] Quintiles, Uppsala, Sweden
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：87S / 87S
页数：1
相关论文
共 50 条
  • [1] Phase I and pharmacological study of KRN951, a potent VEGFR tyrosine kinase inhibitor given in a 4 week on, 2 week off schedule in patients with advanced solid tumors
    Eskens, F. A. L. M.
    de Jonge, M. J. A.
    Van Doorn, L.
    Isoe, T.
    Hayashi, K.
    Hussain, S.
    Ekman, L.
    Burger, H.
    Verweij, J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 16 - 16
  • [2] A phase I dose escalation study of BIBW 2992, an irreversible tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR-1) and 2 (HER 2) in a 2 week on 2 week off schedule in patients with advanced solid tumors.
    Eskens, FA
    Mom, CH
    Planting, AS
    Gietema, JA
    Aamelsberg, A
    Huisman, H
    Verweij, J
    de Vries, EG
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9023S - 9023S
  • [3] A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
    Marshall, John
    Hwang, Jimmy
    Eskens, Ferry A. L. M.
    Burger, Herman
    Malik, Shakun
    Uttenreuther-Fischer, Martina
    Stopfer, Peter
    Ould-Kaci, Mahmoud
    Cohen, Roger B.
    Lewis, Nancy L.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 399 - 408
  • [4] A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
    John Marshall
    Jimmy Hwang
    Ferry A. L. M. Eskens
    Herman Burger
    Shakun Malik
    Martina Uttenreuther-Fischer
    Peter Stopfer
    Mahmoud Ould-Kaci
    Roger B. Cohen
    Nancy L Lewis
    Investigational New Drugs, 2013, 31 : 399 - 408
  • [5] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors.
    Marshall, JL
    Lewis, NL
    Amelsberg, A
    Briscoe, J
    Hwang, J
    Malik, S
    Cohen, R
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9072S - 9072S
  • [6] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors.
    Lewis, N.
    Marshall, J.
    Amelsberg, A.
    Cohen, R. B.
    Stopfer, P.
    Hwang, J.
    Malik, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 143S - 143S
  • [7] A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
    Eskens, Falm
    Mom, C. H.
    Planting, A. S. T.
    Gietema, J. A.
    Amelsberg, A.
    Huisman, H.
    van Doorn, L.
    Burger, H.
    Stopfer, P.
    Verweij, J.
    de Vries, Ege
    BRITISH JOURNAL OF CANCER, 2008, 98 (01) : 80 - 85
  • [8] PHASE I STUDY FOR KRN951 (AV-951), A SELECTIVE VEGFR RECEPTOR 1, 2, 3 TYROSINE KINASE INHIBITOR IN JAPANESE PATIENTS WITH METASTATIC SOLID TUMORS
    Yamaguchi, R.
    Niwakawa, M.
    Onozawa, Y.
    Yasui, H.
    Naito, T.
    Taku, K.
    Yamazaki, K.
    Akinaga, S.
    Boku, N.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2010, 21 : 167 - 168
  • [9] A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
    F A L M Eskens
    C H Mom
    A S T Planting
    J A Gietema
    A Amelsberg
    H Huisman
    L van Doorn
    H Burger
    P Stopfer
    J Verweij
    E G E de Vries
    British Journal of Cancer, 2008, 98 : 80 - 85
  • [10] Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1,-2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
    Eskens, Ferry A. L. M.
    de Jonge, Maja J. A.
    Bhargava, Pankaj
    Isoe, Toshiyuki
    Cotreau, Monette M.
    Esteves, Brooke
    Hayashi, Kunihiko
    Burger, Herman
    Thomeer, Maarten
    van Doorn, Leni
    Verweij, Jaap
    CLINICAL CANCER RESEARCH, 2011, 17 (22) : 7156 - 7163
12345